[The value of platinum dose intensity in first-line therapy on subsequent disease follow-up of epithelial ovarian carcinoma].
Gruböck
K
K
I. Universitäts-Frauenklinik, Wien.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D012189:Retrospective Studies; D015996:Survival Rate
D016190:Carboplatin; D002945:Cisplatin
Die Bedeutung der Platindosisintensität in der first-line-Therapie für den weiteren Krankheitsverlauf beim epithelialen Ovarialkarzinom.